Translational NeuroImaging of the CNS: Novel Pathways to Drug Development

Amyloid-beta–specific reduction in cerebral blood volume CBV determined by fMRI. Functional MRI tracks the dose-dependent decrease in cerebral blood volume caused by the Alzheimer’s plaque–associated amyloid peptide Aβ(1–40). The synthetic peptide that contains the reverse amino acid sequence, denoted as Aβ(40–1), does not elicit the dose-related and region-specific decrease in cerebral blood volume that is associated with Aβ(1–40).